Splenectomy in advanced chronic lymphocytic leukaemia.

Area of Science:

• Hematology
• Oncology

Background:

• Advanced chronic lymphocytic leukemia (CLL) with significant splenomegaly poses treatment challenges.
• Splenomegaly in CLL can be refractory to conventional anti-leukemia therapies.
• Assessing the impact of splenectomy in such cases is crucial for treatment strategies.

Purpose of the Study:

• To evaluate the clinical course and survival of patients with stage C CLL and splenomegaly after splenectomy.
• To compare outcomes with a control group of non-splenectomized CLL patients at the same disease stage.
• To determine the role of splenectomy in managing advanced, treatment-refractory CLL.

Main Methods:

• Retrospective analysis of 20 patients with stage C CLL undergoing splenectomy.
• Comparison with a control group of CLL patients not undergoing splenectomy.
• Evaluation of clinical staging, survival rates, and causes of mortality post-splenectomy.

Main Results:

• Splenectomy led to significant clinical improvement, with 85% reallocated to stage A and 10% to stage B CLL.
• Patients maintained improved stages for over 24 months post-surgery.
• Median survival was 10 years for splenectomized patients versus 3.5 years for controls (p < 0.001).
• Causes of death included disease progression, infections, and unrelated factors.

Conclusions:

• Splenectomy demonstrates a beneficial role in advanced CLL with significant splenomegaly refractory to treatment.
• The procedure improves clinical status and significantly enhances long-term survival.
• Splenectomy should be considered when resistant lymphoid cell accumulation compromises disease control with conventional therapies.